Patents by Inventor Stefan Dengl

Stefan Dengl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-HLA-G antibodies and use thereof
    Patent number: 11981737
    Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: May 14, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jens Fischer, Meher Majety, Stefan Dengl, Georg Tiefenthaler, Stefan Klostermann, Claudia Kirstenpfad, Esther Koenigsberger, Francesca Ros
  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20240101657
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: November 15, 2023
    Publication date: March 28, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • Antibodies binding to NKG2D
    Publication number: 20240067734
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Guy GEORGES, Ralf HOSSE, Inja WALDHAUER, Christian KLEIN, Pablo UMANA
  • Antibody that binds to VEGF and IL-1beta and methods of use
    Patent number: 11866490
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: January 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Joerg Benz, Stefan Dengl, Christian Gassner, Guido Hartmann, Peter Michael Huelsmann, Sabine Imhof-Jung, Kristian Hobolt Jensen, Hubert Kettenberger, Stefan Lorenz, Joerg Moelleken, Olaf Mundigl
  • Antibodies binding to NKG2D
    Patent number: 11827711
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ralf Hosse, Inja Waldhauer, Christian Klein, Pablo Umana
  • Anti-VEGF antibodies and methods of use
    Patent number: 11820816
    Abstract: The present invention relates to anti-VEGF antibodies and methods of their production and their use.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: November 21, 2023
    Assignee: Hoffman-La Roche Inc.
    Inventors: Stefan Dengl, Sebastian Fenn, Guy Georges, Joerg Moelleken, Francesca Ros, Esther Koenigsberger
  • NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY
    Publication number: 20230279090
    Abstract: A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican.
    Type: Application
    Filed: April 14, 2023
    Publication date: September 7, 2023
    Inventors: Stefan Dengl, Rami Hannoush, Simon Theodor Hansen, Peter Michael Huelsmann, Robert Franklin Kelley, Hubert Kettenberger, Shrenik Chetan Mehta, Devin Brent Tesar
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20230265177
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 29, 2022
    Publication date: August 24, 2023
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS
    Publication number: 20230256107
    Abstract: A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 17, 2023
    Inventors: Robert Franklin Kelley, JR., Shrenik Chetan Mehta, Devin Brent Tesar, Rami Hannoush, Simon Theodor Hansen, Stefan Dengl, Hubert Kettenberger, Peter Michael Huelsmann
  • ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH TAILORED AFFINITY
    Publication number: 20230220071
    Abstract: Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 13, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ulrich Goepfert, Jens Niewoehner, Tilman Schlothauer
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20230183349
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: March 3, 2023
    Publication date: June 15, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Laura CODARRI DEAK, Stefan DENGL, Sebastian FENN, Jens FISCHER, Guy GEORGES, Christian KLEIN, Viktor LEVITSKI, Valeria LIFKE, Oliver PLOETTNER, Stefan SEEBER, Barbara WEISER, Ildiko WUENSCHE, Adrian ZWICK
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20230143310
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: June 30, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Anti-transferrin receptor antibodies with tailored affinity
    Patent number: 11584793
    Abstract: Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: February 21, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ulrich Goepfert, Jens Niewoehner, Tilman Schlothauer
  • Humanized anti-Tau(pS422) antibodies and methods of use
    Patent number: 11572404
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 7, 2023
    Assignee: Hoffman-La Rocher Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • NOVEL ICOS ANTIBODIES AND TUMOR-TARGETED ANTIGEN BINDING MOLECULES COMPRISING THEM
    Publication number: 20220098305
    Abstract: The present invention relates to novel ICOS antibodies and tumor-targeted agonistic ICOS antigen binding molecules comprising them, pharmaceutical compositions comprising these molecules, and methods of using the same.
    Type: Application
    Filed: December 15, 2021
    Publication date: March 31, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Tanja FAUTI, Jens FISCHER, Lucas HABEGGER, Christian KLEIN, Esther KOENIGSBERGER, Jens NIEWOEHNER, Johannes SAM, Pablo UMAÑA, Joerg ZIELONKA
  • Method for producing monomeric and multimeric molecules and uses thereof
    Patent number: 11254728
    Abstract: Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (Bn-CSo-Is-CSp-FC-CSq-It-CSr-Bm)u, wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: February 22, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Martin Bader, Stefan Dengl, Stefan Lorenz, Stefan Seeber
  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20220041707
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: September 8, 2021
    Publication date: February 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • METHOD FOR IMPROVING INHIBITION OF VEGF-BINDING TO VEGF-R1 OF AN ANTI-VEGF ANTIBODY
    Publication number: 20220002397
    Abstract: The present invention relates to methods for modulating anti-VEGF antibodies in order to provide variants of an anti-VEGF antibody that exhibit improved inhibition of VEGF binding to VEGF-R1; and antibodies provided by said methods.
    Type: Application
    Filed: June 17, 2021
    Publication date: January 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Stefan Dengl, Andreas Ehler, Sebastian Fenn, Joerg Moelleken
  • CONTORSBODY - A SINGLE CHAIN TARGET BINDER
    Publication number: 20210347916
    Abstract: Herein is reported a circular fusion polypeptide comprising a first part of a binding domain, a second part of a binding domain and a spacer domain, wherein the spacer domain is a polypeptide and comprises at least 25 amino acid residues, the first part of the binding domain is a polypeptide and is fused via a first linker to the N-terminus of the spacer domain, the second part of the binding domain is a polypeptide and is fused via a second linker to the C-terminus of the spacer domain, the first part of the binding domain and the second part of the binding domain are associated with each other and form a binding site that specifically binds to a target.
    Type: Application
    Filed: June 25, 2021
    Publication date: November 11, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Friederike Hesse, Sabine Imhof-Jung, Josef Platzer
  • Antibody that binds to VEGF and IL-1beta and methods of use
    Patent number: 11130804
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 28, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Joerg Benz, Stefan Dengl, Christian Gassner, Guido Hartmann, Peter Michael Huelsmann, Sabine Imhof-Jung, Kristian Hobolt Jensen, Hubert Kettenberger, Stefan Lorenz, Joerg Moelleken, Olaf Mundigl